Furthermore, we believe these findings are likely to have clinical ramifications since aberrant regulation of MYBL2 may affect the sensitivity of tumour cells to inhibitors of the ATM‐dependent DNA damage response. This evidence concerns the gene MYBL2 and neoplasm.